Skip to main content

Table 1 Demographics and baseline characteristics for participants who responded to treatment

From: Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials

Characteristic EM respondersa CM respondersb
Quarterly
fremanezumab
(n = 214)
Monthly
fremanezumab (n = 215)
Quarterly
fremanezumab (n = 218)
Monthly
fremanezumab (n = 210)
Age, mean ± SD, y 41.4 ± 11.7 43.1 ± 12.2 41.9 ± 12.7 41.3 ± 11.9
Body mass index, mean ± SD, kg/cm2 26.9 ± 5.2 26.3 ± 5.4 26.7 ± 5.3 26.5 ± 5.0
Male sex, n (%) 29 (14) 34 (16) 22 (10) 24 (11)
Race, n (%)
 White 171 (80) 178 (83) 171 (78) 171 (81)
 Black/African American 21 (10) 17 (8) 20 (9) 16 (8)
 Asian 20 (9) 18 (8) 22 (10) 21 (10)
 Other 2 (< 1) 2 (< 1) 5 (2) 2 (< 1)
Disease history
 Years since initial migraine diagnosis, mean ± SD 19.9 ± 11.9 20.5 ± 12.8 20.0 ± 12.6 19.8 ± 11.2
 Current preventive medication use, n (%) 40 (19) 44 (20) 41 (19) 45 (21)
 Current use of acute headache medication, n (%) 209 (98) 212 (99) 210 (96) 199 (95)
Disease characteristics
 Monthly migraine days,c mean ± SD 9.3 ± 2.5 9.1 ± 2.6 16.3 ± 4.6 16.0 ± 4.7
 Headache days of any severity,d mean ± SD 8.5 ± 3.2 8.1 ± 3.2 15.5 ± 5.7 15.5 ± 5.5
 Monthly days of acute headache medication use, mean ± SD 7.9 ± 3.6 7.9 ± 3.3 13.0 ± 6.6 13.3 ± 6.9
MIDAS score n = 201 n = 205
Mean ± SD, points 39.2 ± 32.1 37.0 ± 33.4  N/A  N/A
HIT-6 score n = 204 n = 202
Mean ± SD, points  N/A  N/A 64.3 ± 5.0 64.9 ± 4.5
MSQoL domain score, mean ± SD, points n = 211 n = 212 n = 215 n = 208
EF 64.9 ± 23.2 65.5 ± 24.4 57.3 ± 26.4 58.3 ± 25.6
RFP 71.0 ± 17.9 71.7 ± 17.6 66.2 ± 21.1 67.3 ± 21.3
RFR 56.5 ± 16.3 57.3 ± 16.0 47.7 ± 18.6 49.0 ± 18.9
  1. CM Chronic migraine, EF Emotional function, EM Episodic migraine, HIT-6 The 6-item Headache Impact Test, MIDAS Migraine Disability Assessment, MSQoL Migraine-Specific Quality of Life, N/A Not applicable, RFP Role function–preventive, RFR Role function–restrictive, SD Standard deviation, MAMD Monthly average migraine days
  2. aResponders are defined as participants with EM who had a reduction of ≥2 MAMD
  3. bResponders are defined as participants with CM who had a reduction of ≥4 MAMD
  4. cA migraine day was defined as a calendar day in which headache pain lasted ≥4 consecutive hours and met criteria for migraine (with or without aura) or probable migraine (subtype in which only 1 migraine criterion is absent), or a day in which acute migraine–specific medication (triptans or ergots) was used to treat a headache of any duration
  5. dA headache day was defined as a calendar day in which headache pain lasted at least 4 consecutive hours and had a peak severity of at least a moderate level, or a day in which acute migraine–specific medication (triptans or ergots) was used to treat a headache of any severity or duration